EC
LGND icon

Elequin Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Elequin Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6K Sell
13
-21
-62% -$4.16K ﹤0.01% 460
2025
Q4 		$6.43K Buy
+34
New +$6.53K ﹤0.01% 284
2022
Q2 		– Sell
-14
Closed -$1K – 418
2022
Q1 		$1K Buy
+14
New +$1.02K ﹤0.01% 291

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Elequin Capital's LGND Position: Q1 2026 in Review

Elequin Capital reduced its Ligand Pharmaceuticals (LGND) stake by 62% in Q1 2026, selling an estimated $4.16K and leaving 13 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Elequin Capital first reported a position in LGND in Q1 2022 and has held it in 3 quarters since. The position peaked at $6.43K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Elequin Capital held 13 shares of Ligand Pharmaceuticals worth $2.6K as of Q1 2026.
  • Elequin Capital sold 21 Ligand Pharmaceuticals shares in Q1 2026, an estimated $4.16K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Elequin Capital's portfolio in Q1 2026, its #460 holding.
  • Elequin Capital first reported a position in Ligand Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Elequin Capital's Ligand Pharmaceuticals position peaked at $6.43K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.